Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies that are designed to harness the immune system to attack cancer cells. Since we began operations in November 2014, we have built a pipeline of four immuno-oncology programs, three of which focus on the adenosine-cancer axis to modulate an immune response.
CRVS (Common Stock)
$11.32 + 0.01 (0.09%)
05/25/1711:58 a.m. ET
Data provided by Nasdaq. Minimum 15 minutes delayed.